MUC1 and cancer: In Liu’s study, the researchers (including the authors of the current review) constructed nanoparticles to deliver an mRNA vaccine encoding the cancer-associated antigen MUC1 to dendritic cells (DCs) in lymph nodes, thus activating cancer-specific T cells.